Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Myelodysplastic Syndromes 19Lymphoma, Non-Hodgkin 17Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Graft vs Host Disease 13Lymphoma, Mantle-Cell 12Leukemia 12Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 11Sarcoma 10Lymphoma 10Lymphoma, Follicular 9Lymphoma, B-Cell, Marginal Zone 9Burkitt Lymphoma 9Myeloproliferative Disorders 8Waldenstrom Macroglobulinemia 7Tuberous Sclerosis 7Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Hematologic Neoplasms 7Congenital Abnormalities 7Primary Myelofibrosis 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic-Phase 6Leukemia, Myeloid, Accelerated Phase 6Breast Neoplasms 6Osteosarcoma 5

Interventions

Ifosfamide 4Doxorubicin 4Imatinib Mesylate 3Filgrastim 3brostallicin 2Vincristine 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Etoposide 2Dactinomycin 2Cyclophosphamide 2Carboplatin 2temsirolimus 1soblidotin 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1exatecan 1etoposide phosphate 1cixutumumab 1Trabectedin 1Topotecan 1Thiotepa 1Temozolomide 1Surgical Procedures, Operative 1Sirolimus 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fibrosarcoma × Sirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡